title: Posaconazole: promising but problematic in practice in pediatric patients.
abstract: Posaconazole is a broad-spectrum antifungal agent used for the prevention and treatment of invasive fungal infections. It is currently only licensed for use in children greater than 12 years of age. Absorption of the oral formulation is unpredictable and affected by mucositis and concomitant medications. We reviewed studies of posaconazole use in children younger than 12 years in relation to attainment of target serum concentrations.
authors.affiliation: From the *Infectious Diseases and Australian Paediatric Pharmacology Research Unit, The Royal Children's Hospital Melbourne; and †Murdoch Children's Research Institute; and ‡Department of Paediatrics, The University of Melbourne, Victoria, Australia.
authors.forename: Amanda
authors.initials: A
authors.lastname: Gwee
authors.forename: Noel
authors.initials: N
authors.lastname: Cranswick
authors.forename: Nigel
authors.initials: N
authors.lastname: Curtis
mesh_terms: D000293:Adolescent; D000935:Antifungal Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D016469:Fungemia / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D016896:Treatment Outcome; D014230:Triazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use*
chemical_list: D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole